| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3401635 | Enfermedades Infecciosas y Microbiología Clínica | 2013 | 7 Pages |
Abstract
In this model, darunavir/r QD was found to be the most cost-effective choice, among the preferred PI/r-based therapies recommended in the Spanish guidelines for treatment-naïve patients.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
Erik Smets, Anita J. Brogan, Andrew Hill, Ines Adriaenssen, Anthony W. Sawyer, Pere Domingo-Pedrol, Joana Gostkorzewicz, Francisco Ledesma,